Discover the latest on Peloton's leadership changes and workforce adjustments, including CEO Barry McCarthy's transition to a strategic advisor and a 15% reduction in staff due to decreased demand for fitness equipment post-pandemic.

Explore the latest study on obesity treatments in the Obesity journal, analyzing the effectiveness of traditional diets, GLP-1 receptor agonists like semaglutide and tirzepatide, and surgical options such as Roux-en-Y gastric bypass. Learn how these interventions impact weight-loss plateaus.

Life Time (NYSE: LTH) appoints James LaValle as Chief Science Officer to lead MIORA, a new longevity and performance program, with its first clinic at Life Time Target Center in Minneapolis. Learn more about LaValle's role and MIORA’s innovative health services.

Discover how MyFitnessPal is revolutionizing weight loss support with new tools for GLP-1 medication users, enhancing tracking and nutrition management to promote sustainable health improvements. Explore our comprehensive approach to integrating fitness with medication management.

Explore the intricacies of the GLP-1 supplement trend with a focus on consumer health, informed choices, and the importance of professional guidance in the pursuit of wellness.

Explore the Obesity Bill of Rights: An initiative aimed at enhancing access to quality obesity care for Americans. Learn more about this significant healthcare development.

The Ontario government is making big changes in how people can get Ozempic, a medicine mainly used for Type 2 diabetes. This shift is happening because more and more people want Ozempic, especially after celebrities like Oprah Winfrey praised it as a fantastic weight loss solution. This huge demand for Ozempic has caused a shortage in supply. Sadly, it means that people with Type 2 diabetes are finding it harder to get this medicine through the Ontario Drug Benefit (ODB) program.